Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

ts were at least 40 years old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, confirmed by radiographs, and diagnosed according to the ACR guidelines (patients must qualify as ACR global functional status I, II or III). Eligible patients were also current users of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or acetaminophen (paracetamol) for their osteoarthritis pain and these analgesics were withdrawn before treatment with study-drug. The study enrolled both hypertensive and non-hypertensive patients (50.3% of enrolled patients were hypertensive at baseline). There were no statistically significant differences among the four treatment groups for any baseline variables, including hypertension medical history.

About naproxcinod

Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United States during the first quarter of 2009.

NOTE: Within the framework of the ACR annual meeting held in Boston from November 6 to 11, 2007, NicOx had a corporate booth to introduce the Company and its technology to the scientific and medical community in the United States.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 de
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)...  Pifflers United Chronic and Invisible Illnesses Support ... results of a study of ActiPatch®, a new ... fibromyalgia pain. The results demonstrated that when used ... clinically meaningful pain reduction can be achieved. ... used ActiPatch® for 7 days and were then ...
(Date:11/23/2014)... 23, 2014  Aurobindo Pharma USA ... USP 300 mg 100-count bottles to the consumer level. ... empty capsules. Empty capsules could result in ... that could range from no effect, short term reduction ... (long period seizures) that could be life-threatening. Aurobindo Pharma ...
(Date:11/22/2014)... N.J. , Nov. 21, 2014  CytoSorbents ... commercializing its European Union approved CytoSorb® cytokine adsorber ... was awarded the Beacon of Light Award at ... Celebration.  Dr. Phillip Chan ... is an honor to be recognized by the ...
Breaking Medicine Technology:Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... , The Danish Statens Serum Institut (SSI) and Intercell, ... I clinical,trial with a tuberculosis (TB) subunit vaccine , , » ... contains Intercell’s,adjuvant IC31™ , , » ... , replace the available TB,vaccine “BCG”/“Calmette vaccine” ...
... that its,collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) ... of Inflammation,Stops Events) phase III clinical outcomes ... with,antioxidant and anti-inflammatory effects, in patients with,coronary ... not meet its primary endpoint of a,statistically ...
Cached Medicine Technology:Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile 2Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile 3Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile 4Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2
(Date:11/24/2014)... Dr. Michael Kettel , a leading fertility expert ... to discuss egg freezing as a viable and increasingly accessible ... news recently, with new company benefits at Facebook and Apple ... “[The companies] see it as a way to take care ... Says Dr. Kettel. , Up until a few weeks ago, ...
(Date:11/23/2014)... November 24, 2014 The clinical ... 2014" provides data on the Aspergillosis clinical trial ... relating to the clinical trials on Aspergillosis. It ... their recruitment status as per the site of ... a preliminary coverage of disease clinical trials by ...
(Date:11/23/2014)... November 24, 2014 For the coming ... retailer, has launched a great promotion for many products, ... Customers can get the best choice with amazing discounts, ... at Tidebuy.com. , It is easy to buy ... Besides that, this selection is also famous for delicate ...
(Date:11/23/2014)... November 24, 2014 Tbdress.com has ... available online on Nov. 28, 2014. The special offer will ... , Tbdress.com is one of the world’s largest women’s dresses ... and colors. People can enjoy great discounts on that day: ... enjoy free delivery (for orders above $89). , People can ...
(Date:11/23/2014)... York, NY (PRWEB) November 23, 2014 ... that allege heart attacks, strokes, deep vein thrombosis ... filed in a federal multidistrict litigation (MDL) underway ... LLP reports. , Court documents updated on ... Multidistrict Litigation (JPML) show the filing of 259 ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
... adults who have alcohol dependence problems drink significantly more than ... has found. The findings suggest that older problem drinkers ... drink even more than younger abusers to achieve the effects ... adults over age 60 who have alcohol dependence drink more ...
... Ill., Nov. 20 HealthySkinPortal.com is pleased to announce ... cosmetic skin care providers in the HSP national network, ... SmartLipo(TM) body contouring at its locations in Arizona and ... technologies are constantly being introduced. While some providers choose ...
... Nov. 20 Mallika Chopra, healthy living expert and founder ... stress relief products in the US, are teaming up to ... kicks off with advice from Chopra, to be posted today ... holidays without the stress or foreboding that typically comes with ...
... , Unique Survey Takes First-Time Look at Employers, ... 20 More employers are taking steps to improve their ... prescribed, a move that could stave off more serious and ... the National Pharmaceutical Council (NPC). , Medication compliance, sometimes ...
... electronic health records become more widely deployed, increasing amounts ... many beneficial applications, such as research, public health, and ... Khaled El Emam, the Canada Research Chair in Electronic ... there is a need for robust de-identification of patient ...
... ... John,s Riverside Hospital announced it has been granted a full three-year accreditation designation by the ... facility in Westchester County - and one of only four in New York State - ... ...
Cached Medicine News:Health News:Older problem drinkers use more alcohol than do their younger counterparts 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 3Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3Health News:Medication Compliance Is a Key Concern for Employers, According to New Survey 2Health News:Medication Compliance Is a Key Concern for Employers, According to New Survey 3Health News:Ashikari Breast Center Receives Full Accreditation from National Accreditation Program for Breast Centers 2Health News:Ashikari Breast Center Receives Full Accreditation from National Accreditation Program for Breast Centers 3
... Ultra has an uniquely designed ... facility in which tubes are ... the same carrying tray. Spin ... magnifier, quiet operation, automatic electric ...
... The Rotanta 460 family ... extraordinary line that meets ... demands. They feature high ... Their state-of-the-art technology and ...
... Coolscope operates with a simple click ... display. Direct the mouse cursor to ... image of the slide and the ... intuitive Graphic User Interface (GUI) enables ...
Continuous rocking motion graphic display....
Medicine Products: